褪黑素补充对ICU患者睡眠质量及血清褪黑素水平的影响:一项随机对照试验
这项双盲随机安慰剂对照研究纳入两个三级医院多中心ICU的203例接受镇痛和/或镇静的成年患者,比较口服褪黑素10 mg与安慰剂连续最多7晚的效果。结果显示褪黑素组RCSQ睡眠质量评分优于安慰剂组(均值69.7 vs 60.7,p=0.029),极差睡眠比例更低(3.1% vs 14.6%,RR 0.21,95%CI 0.06-0.71),但无镇痛镇静天数、夜间睡眠时长、谵妄、疼痛和焦虑的发生率无显著差异。褪黑素组凌晨2点血清褪黑素峰值显著高于安慰剂组。提示褪黑素可能改善ICU患者睡眠质量,但未改变主要临床结局。
要点
- 在203例接受镇痛和/或镇静的ICU成年患者中,口服褪黑素10 mg连续最多7晚较安慰剂改善RCSQ睡眠质量评分(均值69.7 vs 60.7,p=0.029)。
- 褪黑素组极差睡眠比例3.1%,安慰剂组14.6%,RR 0.21(95%CI 0.06-0.71);极好睡眠比例45.8% vs 34.4%,RR 1.33(95%CI 0.94-1.89)。
- 褪黑素组与安慰剂组在无镇痛镇静天数、夜间睡眠时长、谵妄、疼痛和焦虑发生率上无显著差异。
- 褪黑素组凌晨2点血清褪黑素峰值150 pg/mL(范围125-2125 pg/mL),安慰剂组32.5 pg/mL(范围18.5-35 pg/mL),p<0.001。
适用人群与场景
- 两个三级医院多中心ICU收治的203例成年患者,均接受镇痛和/或镇静治疗。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 口服褪黑素10 mg或安慰剂,连续最多7晚。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:双盲、随机、安慰剂对照研究;样本量203例;两个三级医院多中心ICU;人群为接受镇痛和/或镇静的成年ICU患者;干预为口服褪黑素10 mg连续最多7晚,对照为安慰剂。
- 主要终点(睡眠质量):RCSQ评分褪黑素组均值69.7(SD 21.2) vs 安慰剂组60.7(SD 26.3),p=0.029。
- 极好睡眠比例:褪黑素组45.8% vs 安慰剂组34.4%,RR 1.33(95%CI 0.94-1.89);极差睡眠比例:褪黑素组3.1% vs 安慰剂组14.6%,RR 0.21(95%CI 0.06-0.71)。
- 无显著差异的结局:无镇痛镇静天数、夜间睡眠时长、谵妄发生率、疼痛、焦虑。
- 血清褪黑素:凌晨2点峰值褪黑素组150 pg/mL(范围125-2125 pg/mL) vs 安慰剂组32.5 pg/mL(范围18.5-35 pg/mL),p<0.001。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT)。
- 原文未述证据等级或推荐强度。
- 原文未述局限性。
对床旁实践的改变
- 对于接受镇痛和/或镇静的ICU成年患者,可考虑口服褪黑素10 mg连续最多7晚以改善睡眠质量(RCSQ评分改善)。
- 该干预未显示可减少谵妄、疼痛、焦虑或镇痛镇静需求,不应期望通过这些结局获益。
- 适用人群为ICU成年患者且接受镇痛和/或镇静;不适用人群原文未明确提及。
指南或共识出处
- Crit Care Med
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate whether the use of exogenous melatonin affects sleep, reduces the prevalence of delirium, and decreases the need for analgosedation and to assess whether serum melatonin indices correlate with exogenous administration in critically ill patients.
DESIGN: Double-blind, randomized, placebo-controlled study.
SETTING: Multicenter ICUs of two tertiary hospitals.
PATIENTS: A total of 203 adult patients who were admitted to the ICU and administered with analgesics and/or sedatives.
INTERVENTIONS: Oral melatonin (10 mg) or placebo for up to seven consecutive nights.
MEASUREMENTS AND MAIN RESULTS: The number of observed sleeping hours at night was assessed by the bedside nurse. Sleep quality was evaluated using the Richards Campbell Questionnaire Sleep (RCSQ). The prevalence of delirium, pain, anxiety, adverse reactions, duration of mechanical ventilation, length of ICU and hospital stays, and doses of sedative and analgesic drugs administered were recorded. The use of analgesics and sedatives was assessed daily. Melatonin levels were determined by enzyme-linked immunosorbent assay. Based on the RCSQ results, sleep quality was assessed to be better in the melatonin group than that in the placebo group with a mean (SD) of 69.7 (21.2) and 60.7 (26.3), respectively (p = 0.029). About 45.8% and 34.4% of participants in the melatonin and placebo groups had very good sleep (risk ratio, 1.33; 95% CI, 0.94-1.89), whereas 3.1% and 14.6% had very poor sleep (risk ratio, 0.21; 95% CI, 0.06-0.71), respectively. No significant difference was observed regarding the days free of analgesics or sedatives, the duration of night sleep, and the occurrence of delirium, pain, and anxiety. Melatonin serum peak levels at 2 AM were 150 pg/mL (range, 125-2,125 pg/mL) in the melatonin group and 32.5 pg/mL (range, 18.5-35 pg/mL) in the placebo group (p < 0.001).
CONCLUSIONS: Melatonin was associated with better sleep quality, which suggests its possible role in the routine care of critically ill patients in the future.
参考来源
- Gandolfi JV, Di Bernardo APA, Chanes DAV, et al. The Effects of Melatonin Supplementation on Sleep Quality and Assessment of the Serum Melatonin in ICU Patients: A Randomized Controlled Trial. Crit Care Med. 2020. PMID: 33048904. doi:10.1097/CCM.0000000000004690
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。